Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab. [Eine doppelblinde, placebo-kontrollierte, randomisierte, multizentrische Phase II Studie zur Behandlung von Hauttoxizitäten bei Patienten mit metastasierten kolorektalen Karzinomen, die Panitumumab erhalten]

Next Previous
Trial Profile

SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab. [Eine doppelblinde, placebo-kontrollierte, randomisierte, multizentrische Phase II Studie zur Behandlung von Hauttoxizitäten bei Patienten mit metastasierten kolorektalen Karzinomen, die Panitumumab erhalten]

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxycycline (Primary) ; Panitumumab
  • Indications Bacterial infections; Skin infections
  • Focus Therapeutic Use
  • Acronyms SKIP

Most Recent Events

  • 14 Jul 2014 Biomarkers information updated
  • 17 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 07 Jul 2012 Actual initiation date (2 May 2011) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top